Navigation Links
Mammalian Expression Vectors with Interchangeable Selectable Markers


Site-specific recombinase-based vector system

Lisa Marsh Carsten Carstens
Stratagene

Stratagenes Exchanger system of eukaryotic expression vectors offers unparalleled convenience. The drug-resistance genes of these vectors can be exchanged without subcloning. Through site-specific recombination, hygromycin, puromycin, and neomycin functional cassettes are quickly and efficiently inserted into the pExchange core vectors. Insertion is carried out in vitro by a Cre-mediated recombination of LoxP sites, and recombination products are selected via drug resistance. The components of the Exchanger system include Cre recombinase; one of the six different pExchanger core vectors; linearized insertion modules, which are flanked by LoxP sites and provide hygromycin, puromycin, or neomycin resistance for selection in mammalian cells; the corresponding luciferase core-vector control; and supercompetent Epicurian Coli XL1-Blue cells. The entire site-specific recombination procedure consists of a 30-minute recombination reaction, a 15-minute heat inactivation, and transformation of suitable hosts with the recombination reaction. Desired reaction products are obtained with greater than 90% efficiency.

Stratagenes pCMV-Script and pCMV-Tag mammalian expression vectors1,2,### offer easy cloning and high-level expression; accordingly, they are used in a variety of standard molecular biology applications. These vectors, in addition to containing an expression cassette for inserting the gene of interest into a multiple cloning site, usually include a cassette that contains a selectable marker. However, when it is necessary for the expression vector to carry a different selectable marker, the most common method is to subclone the gene of interest into a different vector, which is very inconvenient. Therefore, it would be ideal to be able to quickly and efficiently exchange drug-resistance elements without subcloning into such vectors.

Cre-Mediated Recombination

To eliminate conventional restriction digestion and ligation subcloning procedures, site-specific recombination is used to manipulate DNA fragments. Site-specific recombinases, such as the P1-derived Cre recombinase, catalyze the exchange of DNA located between specific recognition sequences.3,4,5 For Cre recombinase, the recognition site (LoxP) consists of two inverted 13-bp repeats and an intervening, 8-bp nonpalindromic region.3 Intermolecular and intramolecular recombination between the two sites can occur.

Exchange of Selectable Markers

Fig.1

Stratagenes Exchanger cloning system is based on Cre-mediated, site-specific recombination, which allows fast and efficient insertion of prefabricated, selectable DNA fragments into core expression vectors. The system consists of a pExchange core expression vector, drug-resistance modules and Cre recombinase protein. The pExchange core vectors are based on the pCMV-Script and pCMV-Tag vectors vectors (Figure 1) that contain a LoxP site that serves as the acceptor site for the eukaryotic selectable-marker cassettes and offer a variety of expression options. The hygromycin-, puromycin-, or neomycin-resistance modules (Figure 2) are designed to be inserted into the LoxP site of either core vector. Each cassette is linearized and flanked by LoxP sites. A luciferase-containing core vector control for verifying expression in any cell line is provided along with Epicurian Coli XL-1 Blue supercompetent cells for simplifying transformation. All components are available separately.

Fig.2

The essential process for Cre-mediated insertion of antibiotic-resistance cassettes into the core vectors of the Exchanger system is described in Figure 3. Recombination requires a 30-minute incubation of the core vector, antibiotic-resistance cassette, and Cre recombinase. This reaction is followed by heat inactivation of Cre recombinase at 65C for 15 to 30 minutes. The inactivated recombination reaction is then used to transform host cells, and the transformation mixture is selected on the appropriate antibiotic-containing nutrient plates. After incubation, colonies are picked and screened using standard miniprep procedures, and plasmid DNA can be analyzed by restriction digestion. Successful insertion rates of greater than 90% are achieved routinely.

Fig.3

Functional Testing of the Selectable Cassettes

To test the performance of the eukaryotic selectable markers provided by each cassette, we transfected Chinese hamster ovary (CHO) and NIH3T3 cells with the core vector containing the selectable marker that was introduced by site-specific recombination. Each construct conferred resistance to the respective drug at a frequency equal to or better than comparable vectors with the same drug resistance marker (data not shown).

To confirm the functionality of the CMV expression cassettes of the core vectors, we compared luciferase expression from the pExchange core vectors to luciferase expression from the parental pCMV-Script and pCMV-Tag vectors. In these transient transfections of CHO cells, the presence of the integrated drug-resistance cassettes did not affect the performance of the CMV expression cassette in luciferase expression assays. The observed expression level of the Exchanger system vectors did not differ from their respective parental pCMV-Script and pCMV-Tag vector constructs (data not shown).

Conclusions

Stratagenes Exchanger vector system allows a single expression construct to be used for multiple applications without subcloning the gene of interest. This system features the pExchange core vectors into which, through Cre-mediated site-specific recombination, hygromycin-, puromycin-, or neomycin-resistance selection cassettes can be introduced. Several test experiments have verified that the desired recombinants are generated with greater than 90% efficiency. While eliminating tedious subcloning procedures, the Exchanger vector system provides an easy mechanism for inserting selectable markers.

REFERENCES

  1. Hosfield, T. and Lu, Q. (1997) Strategies 10: 116-118.

  2. Abremski, K., Hoess, R., and Sternberg, N. (1983) Cell 32: 1301-1311.

  3. Broach, J.R., Guarascio, V.R., and Jayaram, M. (1982) Cell 29: 227-234.

  4. Landy, A. (1989) Annu. Rev. Biochem. 58: 913-949.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. New Mammalian Two-Hybrid System Detects Protein-Protein Interactions
2. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
3. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
4. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
5. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
6. A New Lambda Vector for Mammalian Expression
7. Mammalian and Bacterial Expression in One Vector
8. Mammalian Expression Vector for Efficient Cloning of PCR Fragments
9. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
10. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
11. Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):